Iovance Biotherapeutics is trading 4.12% up at $8.47 after management highlighted stronger Amtagvi commercial momentum.
- Management discussed the momentum at the Wells Fargo Healthcare Conference.
- Real-world response rates above 50% and manufacturing efficiencies lifted gross margins to 56%.
- The cash runway extends through 2028, while major indexes rose more than 1% on September 11, 2026.